China's Akeso Bets On IO Antibody Combo With First US IND

 
• By Brian Yang
  
Emerging Company Profile Regular column feature image Version 2
Chinese Bioventure Akeso Has Obtained An IND For Its Lead Asset • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer